![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Paul Earnshaw
Paul Earnshaw has worked in the biotech and pharmaceutical industry for the past 22 years. After nine years at Genentech serving in both Manufacturing and Quality roles, he transitioned into Business Development for Eppendorf where he sold and supported their bioreactors and fermentors for eight years. For the past five years he has supported Vetter Pharma’s clinical manufacturing sites in Chicago and Rankweil, Austria.
Company:Vetter
Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 5,700 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.
